cbdMD (NYSE American: YCBD) has announced the strategic acquisition of closely held Bluebird Botanicals through an asset purchase comprised of an initial share issuance and earnout shares.
According to cbdMD, the acquisition brings together two mission-aligned brands that share a focus on quality and consumer experience. Bluebird Botanicals has cultivated a loyal consumer following over more than a decade and attracted backing from Juggernaut Capital Partners, a middle-market private equity firm focused on consumer and healthcare investments with a track record of scaling premium wellness and consumer brands.
In a statement, Ronan Kennedy, CEO of cbdMD, commented, “Our team has long admired Bluebird Botanicals for its authenticity, product integrity, and the trust it has cultivated in the hemp community. This partnership amplifies our shared commitment to elevating wellness solutions and delivering unmatched value to consumers nationwide.”
